India's Torrent Pharma posts profit boost on strong demand for chronic illness drugs

J B Chemicals and Pharmaceuticals

07/11/2025 13:00

Nov 7 (Reuters) - Indian drugmaker Torrent Pharma TORP.NS reported a 30.5% rise in its second-quarter profit on Friday, driven by strong domestic demand for its cardiovascular and anti-diabetic drugs.

The company reported consolidated net profit of 5.91 billion rupees ($67.24 million) for the quarter ended September 30.

Overall revenue rose 14.3% to 33.02 billion rupees.

For further earnings highlights, click here.

KEY CONTEXT

The Indian pharmaceutical market grew 7.3% in value in September, driven by strong sales in cardiovascular, anti-diabetic, and anti-infectives therapies, according to data from PharmaRack.

The demand boosted Torrent Pharma's domestic revenue, which accounts for more than half of overall revenue, by 12% to 18.2 billion rupees.

To further boost sales, Torrent Pharma launched new products and has diversified its portfolio by buying a majority stake in JB Chem and Pharma JBCH.NS.

PEER COMPARISON

Valuation (next 12 months)
Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Price/Sales
Revenue growth (%)
Profit growth (%)
Mean rating
# of analysts
Stock to price target
Div yield (%)
Torrent Pharmaceuticals
TORP.NS
43.88
26.08
7.80
12.30
23.74
BUY
29
0.91
0.90
Mankind Pharma
MNKI.NS
42.07
25.95
6.49
15.94
18.57
BUY
16
0.88
0.04
J B Chemicals and Pharmaceuticals
JBCH.NS
29.85
19.56
5.43
11.37
18.06
BUY
11
0.83
0.74
Sun Pharmaceutical Industries
SUN.NS
31.68
21.51
6.22
9.80
8.18
BUY
37
0.86
0.97

 * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

JULY TO SEPTEMBER STOCK PERFORMANCE

-- All data from LSEG

-- $1 = XX Indian rupees

($1 = 87.8950 Indian rupees)

TORRENT PHARMA'S STOCK PERFORMANCE IN Q2 COMPARED TO PEERS https://reut.rs/4mWc179

 (Reporting by Kashish Tandon and Mridula Kumar in Bengaluru; Editing by Janane Venkatraman)

 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))